Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

AIDS (London, England) - 24 Aug 2009

Ho Sarah K, Perez Elena E, Rose Stephanie L, Coman Roxana M, Lowe Amanda C, Hou Wei, Ma Changxing, Lawrence Robert M, Dunn Ben M, Sleasman John W, Goodenow Maureen M

Abstract excerpt

OBJECTIVE: To identify novel viral determinants in HIV-1 protease, Gag, and envelope V3 that relate to outcomes to initial protease inhibitor-based antiretroviral therapy. DESIGN: A longitudinal cohort study of protease inhibitor-naive, HIV-infected individuals was designed to identify genetic variables in viral Gag and envelope sequences associated with response to antiretroviral therapy. METHODS: Genetic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to gag Gene Products, Human Immunodeficiency Virus

Share to HIV Envelope Protein gp120

Share to HIV Protease Inhibitors

Share to Peptide Fragments

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 19625947
DOI: 10.1097/QAD.0b013e32832e0599
PMCID: PMC3656663

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.PMID 19625947Read ↗

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.Semantic proximity Read ↗

Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients.Semantic proximity Read ↗

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.Semantic proximity Read ↗

Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection.Semantic proximity Read ↗

Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.Semantic proximity Read ↗

Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.Semantic proximity Read ↗

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.Semantic proximity Read ↗

Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.Semantic proximity Read ↗

Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.Semantic proximity Read ↗

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.Semantic proximity Read ↗

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.